Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome- Outcome in Previously Untreated Patients.

Gautam Borthakur, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, Marina Konopleva, MD, PhD, Jan A. Burger, MD, PhD, Deborah A. Thomas, MD, Tapan Kadia, MD, Betsy Williams, RN, Solly George, Hagop Kantarjian, MD

Blood (2009) 114 (22): 1053.

https://doi.org/10.1182/blood.V114.22.1053.1053

Published: 2009

Journal Articles

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

Gautam Borthakur, MD, Zeev Estrov, Guillermo Garcia-Manero, MD, Betsy Williams, Jay K. Wathen, Marina Konopleva, Jan Burger, Alessandra Ferrajoli, Solly George, Hagop Kantarjian

Blood (2008) 112 (11): 2985.

https://doi.org/10.1182/blood.V112.11.2985.2985

Published: 2008

Journal Articles

Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy

Farhad Ravandi, MBBS, Deepa Sampath, PhD, William Plunkett, PhD, Betsy Williams, RN, Michelle Burton, RN, Srdan Verstovsek, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Vernon Alvarez, PhD, Michael D Becker, Alan F. List, MD, Said Sebti, PhD, Hagop M. Kantarjian, MD, Jeffrey Lancet, MD

Blood (2008) 112 (11): 2987.

https://doi.org/10.1182/blood.V112.11.2987.2987

Published: 2008

Journal Articles

Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (FTS), a Novel Oral Ras Inhibitor, in Patients with Refractory Hematologic Malignancies.

Gautam Borthakur, MD, Farhad Ravandi, MD, Susan O’Brien, MD, Miloslav Beran, MD, Betsy Williams, RN, Howard Goldsweig, MD, Francis Giles, MD

Blood (2007) 110 (11): 1600.

https://doi.org/10.1182/blood.V110.11.1600.1600

Published: 2007

Journal Articles

Phase I Study of Triciribine Phosphate Monohydrate, a Specific Inhibitor of AKt Phosphorylation, in Adult Patients with Advanced Hematologic Malignancies.

Farhad Ravandi, MD, Jeffrey Lancet, MD, Francis Giles, MD, William Plunkett, PhD, Betsy Williams, RN, Michelle Burton, RN, Stefan Faderl, MD, Zeev Estrov, MD, Gautam Borthakur, MD, Lawrence Akinsanmi, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 913.

https://doi.org/10.1182/blood.V110.11.913.913

Published: 2007

NARROW

Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome- Outcome in Previously Untreated Patients.

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy

Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (FTS), a Novel Oral Ras Inhibitor, in Patients with Refractory Hematologic Malignancies.

Phase I Study of Triciribine Phosphate Monohydrate, a Specific Inhibitor of AKt Phosphorylation, in Adult Patients with Advanced Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome- Outcome in Previously Untreated Patients.

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome

Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy

Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (FTS), a Novel Oral Ras Inhibitor, in Patients with Refractory Hematologic Malignancies.

Phase I Study of Triciribine Phosphate Monohydrate, a Specific Inhibitor of AKt Phosphorylation, in Adult Patients with Advanced Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only